Armata Pharmctcl Stock Price, News & Analysis

Innoviva reported a 5% increase in first-quarter royalties, totaling $93.5 million compared to Q1 2021. Notable earnings included $55.8 million from RELVAR®/BREO® ELLIPTA® and $29.3 million from TRELEGY® ELLIPTA®. However, income from operations saw a 2% decrease to $77.7 million due to the accounting consolidation of Entasis. Innoviva made a strategic investment of $45.0 million in Armata Pharmaceuticals and a $15.0 million offer to acquire Entasis, amidst a $9.4 million decline in asset fair values.

Armata Pharmaceuticals has successfully closed the second tranche of a $45 million private placement with Innoviva, raising approximately $26.9 million through the issuance of over 5.3 million common shares and 2.7 million warrants. This follows an initial tranche completed in February 2022 that raised $18.1 million. As of March 31, 2022, Armata has 36.1 million shares outstanding. Furthermore, their Form 10-K filed on March 17, 2022, includes a going concern note. Approximately 99% of shareholders voted in favor of the transaction, indicating strong support for the company's direction.

Armata Pharmaceuticals (ARMP) reported its fourth quarter and full year 2021 financial results, highlighting significant clinical advancements and a $45 million equity financing with Innoviva, Inc., its largest shareholder.

The company optimized its AP-PA02 cocktail to cover 90% of tested Pseudomonas aeruginosa isolates, began a Phase 2 trial for non-cystic fibrosis bronchiectasis, and advanced AP-PA03 manufacturing. Armata's cash position improved to $10.3 million, bolstered by grant revenue and ongoing partnerships.

A joint venture involving HATCHspaces, NexCore Group, and Nuveen Real Estate has acquired a 56,300 sq ft industrial facility in Playa Vista, West Los Angeles. This site will be redeveloped into a cGMP biomanufacturing facility, serving as the headquarters for Armata Pharmaceuticals (NYSE: ARMP). The facility aims to produce treatments for antibiotic-resistant infections, addressing a critical need in the life sciences sector. This acquisition marks the fifth asset for the HATCH/NexCore venture, which now controls over 500,000 sq ft of life sciences space in the region.

Armata Pharmaceuticals (NYSE American: ARMP) announced FDA clearance for its Investigational New Drug application to initiate a Phase 2 clinical trial of AP-PA02 for non-cystic fibrosis bronchiectasis (NCFB). This condition, often linked to lung infections, currently has no approved treatments. The trial aims to assess the efficacy of AP-PA02 against Pseudomonas aeruginosa infections. Additionally, Armata is advancing other candidates for various bacterial infections, supported by recent financing.

Armata Pharmaceuticals (NYSE American: ARMP) announced its participation in two investor conferences in February and March 2022. The first event is BioCom California's 12th Annual Global Life Science Partnering Conference, taking place from February 22-24, where Pierre Kyme will present on February 23 at 3:30 PM PT. The second event is the 2nd Annual Chardan Microbiome Medicines Summit on March 1, featuring Brian Varnum at 10:00 AM ET. Armata specializes in bacteriophage therapeutics targeting antibiotic-resistant infections.

Innoviva reported substantial financial results for Q4 and full year 2021, with royalties rising by 18% to $111.1 million for Q4 and 19% to $405.7 million for the full year. Income from operations increased by 23% to $104.5 million in Q4 and 17% to $375.1 million for the year. Despite a $42.9 million decline in fair values of investments due to market volatility, the overall position remained strong with $201.5 million in cash and equivalents. A strategic investment of $45.0 million in Armata Pharmaceuticals is also highlighted.

Armata Pharmaceuticals announced a securities purchase agreement to sell common stock and warrants to Innoviva, raising $45 million before expenses. The funding will support Armata's clinical pipeline, particularly for AP-PA02 and AP-SA02, which target chronic Pseudomonas aeruginosa infections and complicated Staphylococcus aureus bacteremia, respectively. Innoviva will purchase 9 million shares at $5.00 each, with transactions occurring in two tranches. The second tranche is contingent on shareholder approval and is expected by the end of Q1 2022.

Armata Pharmaceuticals (NYSE American: ARMP) announced enhancements to its lead bacteriophage product candidate, AP-PA02, increasing its potency and coverage against Pseudomonas aeruginosa strains in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. The new formulation introduces two additional phage genera, achieving over 90% coverage of tested isolates. Armata plans to enter a Phase 2 trial for non-cystic fibrosis bronchiectasis in 2022. The company is also developing a distinct phage cocktail for pneumonia. These advancements align with Armata's strategy to improve bacteriophage therapy effectiveness.